Clinical trial NCT05365789: A Nasal Spray for Relief of Nasal Congestion in Infants and Toddlers With Common Cold
Official title: A Trial to Evaluate Efficacy and Safety of a Nasal Spray Combined With Standard of Care for Nasal Congestion in Infants and Toddlers With Common Cold in Comparison to Standard of Care Alone
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nasal Congestion
Keywords: Pediatric
Lead sponsor: Church & Dwight Company, Inc.
Sponsor class: INDUSTRY
First posted: 2022-05-09
Enrollment: 220
Sex: ALL
Minimum age (years): 3
Maximum age (years): 48
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Open label, randomized, parallel group. Study product and standard of care versus standard of care.
Primary purpose: TREATMENT

Brief summary: The study will evaluate the safety and efficacy of the study medical device plus standard of care versus standard of care in subjects between 3 and 48 months (inclusive) presenting symptoms of a common cold.

Detailed description: The purpose of the present study is to test the efficacy, safety and tolerability of a product in relieving the symptoms of the common cold in children. This nasal spray is specifically studied for small children, classified as medical devices and is already on the market. Sterimar Blocked Nose Baby (CDEU048-28) nasal spray is a medical device and is a 100 ml bag-on-valve spray. The spray contains hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and copper.

220 subjects will be included in this open label, randomized, parallel group, study product and standard of care versus standard of care study.

Study product will be used as 1 to 2 sprays per nostril (each "dose" is 1 or 2 sprays per nostril, the second spray only if needed), for a minimum of 2 times (morning and evening) and, as needed, up to a maximum of 6 times per day (i.e., maximum 12 sprays per nostril each day). The 10 day study consists of 4 visits- Day 0 onsite, Days 3 and 6 telephone contact, and Day 10 onsite.

There will be 3 strata according to age: (3-12 months), (13-24 months) and (25-48 months). Every effort will be made to ensure at least 20% of subjects in each of the study groups are 3-12 months of age.

Eligibility criteria: Inclusion Criteria:

1. Male and female infants and toddlers.
2. Aged 3 - 48 months (inclusive) at enrolment (Day 0).
3. Parent/legal guardian answering "yes" to the question "Do you feel that your child has a cold?" at enrolment.
4. Subjects with symptoms started not later than 48 hours prior to enrolment (Day 0).
5. Subjects with nasal congestion (blocked / stuffy nose) rated as at least score of 2 (moderately bothersome) on a 0 to 3-point scale, based on morning evaluation (within an hour of child awakening).
6. Subjects showing at least one of the following additional signs of cold symptoms: runny nose, nasal crust (dry mucus), thick mucus, sneezing and cough.
7. Parent/legal guardian of the subject has given freely and expressly her/his informed consent.
8. Parent/legal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected.

Exclusion Criteria:

1. Subjects presenting an oral temperature greater than 38°C at enrolment (Day 0).
2. Subjects presenting any secondary infection (such as bronchitis, otitis, tracheitis, pneumonia, etc.) at enrolment (Day 0).
3. Subjects with positive results on a streptococcal antigen screening test (rapid antigen detection test or RADT) at inclusion.
4. Subjects with a history of allergic rhinitis
5. Subjects presenting any congenital or chronic disease that in the opinion of the Investigator would adversely affect the results of the study (e.g. asthma, pneumonia, laryngotracheobronchitis, sinusitis, etc).
6. Subjects presenting any kind of immunodeficiency.
7. Subjects presenting any hypersensitivity or allergy or intolerance to any component of the study products or of the rescue medication (paracetamol)
8. Subjects with a positive medical history to any significant illness within the 2 weeks prior to the enrolment (Day 0).
9. Subjects presenting any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study.
10. Subjects currently participating or having participated in another clinical trial during the last 30 days prior to enrolment (Day 0).
11. Subjects using saline nose drops or nasal sprays or pumps other than the study products, antibiotics, antivirals, intranasal medicines, decongestants, antihistamines, echinacea, combination cold formulas, supplements containing ≥ 10 mg zinc that would influence symptoms scores at enrolment (Day 0) within 12 hours prior the day of screening
12. Subject who was abroad in a country with a higher incidence rate of Covid-19 than Poland, within 14 days before the beginning of the study.
13. Subject who have had contact with any person infected with COVID-19 within 10 days before the beginning of the study.
14. Subject who are currently home quarantined, as recommended by the Sanitary Inspection.

Primary outcomes:
measure: Change of nasal congestion
timeFrame: Through study completion, an average of 10 days.
Secondary outcomes:
measure: Change of other cold symptoms
timeFrame: Through study completion, an average of 10 days.
measure: Occurrence of secondary infections
timeFrame: Through study completion, an average of 10 days.
Other outcomes:
measure: Onset of relief
timeFrame: assessed at 5, 15, and 30 minutes post first application of device every morning from Day 0 to 3
measure: Concomitant medications
timeFrame: Through study completion, an average of 10 days.
measure: Frequency of paracetamol administration.
timeFrame: Through study completion, an average of 10 days.
measure: Quality of sleep.
timeFrame: Through study completion, an average of 10 days.
measure: Global assessment on common cold status.
timeFrame: Through study completion, an average of 10 days.
Locations:
city: Sztum
country: Poland
facility: PRIVATE PRACTICE ul. Osiedle Sierakowskich 5
Study officials:
affiliation: Private Practice
name: Anna Rynkiewicz, MD
role: PRINCIPAL_INVESTIGATOR
References: